
New Federal Rules That Lower Barriers to Opioid Care Could Save Thousands of Lives
The two main medications that treat opioid use in the United States reduce overdose deaths by 50%. Yet fewer than one in 10 people with opioid use disorder (OUD) can access this kind of medical protocol, according to the Centers for Disease Control and Prevention (CDC). Fortunately, a new law and a new federal regulation […]

Characterizing Initiation, Use, and Discontinuation of Extended-Release Buprenorphine in a Nationally Representative United States Commercially Insured Cohort
Medications for opioid use disorder (MOUD) are evidence-based treatments that help people reduce or stop using opioids. However, high discontinuation rates of MOUD pose a barrier to reducing opioid-related overdoses. Extended-release buprenorphine (XR-BUP) is a relatively new MOUD, approved in late 2017, that has the potential to increase retention because of its monthly dosing schedule. Currently, there is […]

Achieving Value in Substance Use Disorder Treatment: Paying for What Works (and Not Paying for What Doesn’t): Workshop Summary
More than 100 policymakers, practitioners, and researchers discussed and debated how payment policy can promote evidence-based, cost-effective substance use disorder treatment, in a recent workshop hosted by the Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV and HIV (CHERISH) and the Leonard Davis Institute of Health Economics at the University of […]
Engage with CHERISH
Submit a Consultation Request or Contact Us to learn more about how CHERISH can support your research or policy goals.